Senior Management Team

Dr. Gary Jennings CSO and Co-Founder Dr. Jennings has over 13 years experience in the commercial biotechnology industry. As a co-founder of JADO, Dr. Jennings led the company through its early start-up stages until August 2007. Recently he has become solely focused on spearheading the Company’s research and development efforts as Chief Scientific Officer. Previously, he gained industrial experience at Ribonetics GmbH and as Head of Cell Engineering at HepaVec AG (Berlin) and DeveloGen AG (Göttingen). As a trained biochemist he worked on liver carcinogenesis at the Institute of Toxicology, University of Mainz, Germany, before moving to the Max-Delbrück Center of Molecular Medicine (Berlin) to study tissue engineering. Dr. Jennings received his PhD from the University of York (UK).

 

Dr. Tobias Braxmeier Head of Chemistry and Intellectual Property Dr. Tobias Braxmeier has more than eight years experience in drug development. As Head of Chemistry and Intellectual Property he is responsible for the chemical sciences and for designing and executing JADO's intellectual property. Prior to joining JADO in 2003, he was a Senior Scientist at NAD AG, a Munich-based spin-off from Bayer AG, where he was project manager in discovery and preclinical drug development of kinase inhibitors for neurodegenerative diseases. As member of the team delivering the first BBB-penetrating kinase inhibitor for treatment of Alzheimer's disease he contributed to a successful proof-of-concept study in a transgenic mouse model. Dr. Braxmeier holds a PhD in Chemistry from the University of Karlsruhe (1998) and conducted his postdoctoral studies at the University of Southampton (UK).

 

Ines Kaestner Head of Finance and Administration Ms. Kaestner has over 10 years’ management experience, of which the past 5 years have been spent in the financial sector of the biotechnology industry. At JADO, she is responsible for strategic financial management, financial controlling, corporate governance and investor relations. She joined JADO in October 2003 and has participated in three successful financing rounds. Prior to her appointment at JADO, she worked at the Max Planck Institute of Molecular Biology and Genetics and supported the directors in setting up the new institute in Dresden. Ms. Kaestner holds a degree in business administration and is currently completing her MBA studies at the Henley Business School (UK).